arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Aurinia Pharmaceuticals Inc.

AUPH
$16.20 ▼ -0.93 (-5.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Aurinia Pharmaceuticals Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.2B
Dividend Yield —
Revenue Growth 13.9% ↘
Op. Margin 42.3% ↘
ROIC 4.4% ↘
FCF / Share $0.35 ↘
Trailing P/E 67.5x
Price / Book 3.3x
FCF Yield 2.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$83.70M
↑ +13.9% —
Net Income Profit after all expenses
$34.35M
↑ +47.2% —
Operating Margin Operating profit as % of sales
42.3%
↓ -24.1% 92th
FCF / Share Free cash flow per share
$0.35
↓ -14.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
95
Returns
97
Cash Quality ↓
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 31 quarters